Form 4: Alkermes EVP Craig C. Hopkinson Reports Sale of Ordinary Shares
SEC Form 4 Filing
Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reported the sale of 10,471 ordinary shares on November 6, 2024, at a weighted average price of $29.5262.
Summary
- On November 6, 2024, Craig C. Hopkinson, the EVP R&D and Chief Medical Officer of Alkermes plc, sold 10,471 ordinary shares of the company.
- The sale was executed at a weighted average price of $29.5262 per share.
- The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following the transaction, Hopkinson directly owns 99,238 ordinary shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of an insider transaction under a pre-existing trading plan.
Industry Context
This is a routine disclosure of insider trading activity. It is common for executives to have pre-arranged trading plans to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 12/14/2023 | Date the reporting person adopted a Rule 10b5-1 trading plan |
| 11/06/2024 | Date of the transaction (sale of shares) |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.